Immunovant To Stop Development Of IMVT-1402 In Cutaneous Lupus Erythematosus

Immunovant reported that Period 1 of its proof-of-concept trial for IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus did not achieve statistical significance on its primary endpoint. The failed primary endpoint is a material clinical-development setback that could pressure Immunovant shares and increase uncertainty around the program's future development path.